Results 181 to 190 of about 286,873 (209)

DEXAMETHASONE INTRAVITREAL IMPLANT FOR CHOROIDAL NEOVASCULARIZATION DURING PREGNANCY

RETINAL Cases & Brief Reports, 2019
Purpose: To describe the management of active choroidal neovascularization (CNV) during pregnancy with the use of a dexamethasone intravitreal implant (DXI) (Ozurdex). Methods: Case series of active CNV treated with DXI with at least 12-month follow-up retrospectively analyzed at 2 ...
Capuano V., Serra R., Oubraham H., Zambrowski O., Amana D., Zerbib J., Souied E. H., Querques G.   +7 more
openaire   +3 more sources

EFFECT OF INTRAVITREAL DEXAMETHASONE IMPLANT ON THE CONTRALATERAL EYE

RETINAL Cases & Brief Reports, 2013
Purpose: To describe the effect of unilateral intravitreal injection of 0.7-mg dexamethasone implant on the other eye. Methods: Interventional case report and literature review. Results: A 54-year-old woman with bilateral, refractory ...
Ashish, Sharma, Jay, Sheth, Rangasamy J, Madhusudan, Selva K, Sundaramoorthy   +3 more
openaire   +2 more sources

Macular Hole Closure With Intravitreal Dexamethasone Implant

Ophthalmic Surgery, Lasers and Imaging Retina, 2023
Arsalan A, Ali, Ashkan M, Abbey
openaire   +2 more sources

Intravitreal Dexamethasone Implant in Vitreoretinal Surgery: An Overview of the Literature

Graefe's Archive for Clinical and Experimental Ophthalmology
The sustained-release intravitreal 0.7 mg dexamethasone implant (DEX implant) (Ozurdex®, Allergan®, an AbbVie Company, North Chicago, Illinois, USA) is widely used to treat various inflammatory retinal disorders. Notably, its application is expanding in the field of vitreoretinal surgery.We conducted a comprehensive literature search across the Web of ...
Boscia G., Feo A., Savastano A., Viggiano P., Landini L., Clemente A., Scotti G., Grassi M. O., Parisi G., Giancipoli E., Alessio G., Boscia F., Mastropasqua R., Reibaldi M., Romano M. R., Borrelli E.   +15 more
openaire   +2 more sources

Failure of intravitreal dexamethasone implant application

2020
Intravitreal dexamethasone implantation (IVDI) has been introduced for indications of retinal venous occlusion, diabetic maculopathy and macular edema due to posterior uveitis. A 65-year-old man, who developed bilateral diabetic macular edema and had limited response to bilateral intravitreal anti-vascular endothelial growth factor injections, was ...
Aras, Ferişte, Ulas, Fatih
openaire   +1 more source

Re: Intravitreal dexamethasone implant fragmentation

Canadian Journal of Ophthalmology, 2013
Javier, Cabrerizo, Gonzaga, Garay-Aramburu   +1 more
openaire   +2 more sources

Dexamethasone Intravitreal Implant During Phacoemulsification

Ophthalmology, 2013
Aniruddha, Agarwal, Vishali, Gupta, Jagat, Ram, Amod, Gupta   +3 more
openaire   +2 more sources

Safety and Efficacy of Dexamethasone Intravitreal Implant Given Either First-Line or Second-Line in Diabetic Macular Edema

Patient Preference and Adherence, 2023
Vincenzo Scorcia, Giulia Coco, Giuseppe Giannaccare   +2 more
exaly  

Dexamethasone biodegradable intravitreal implant

2013
David Callanan, Robert Wang
openaire   +1 more source

Intravitreal Dexamethasone Implant as a Sustained Release Drug Delivery Device for the Treatment of Ocular Diseases: A Comprehensive Review of the Literature

Pharmaceutics, 2020
Rossella D'Aloisio, Giacinto Triolo, Marco Pellegrini   +2 more
exaly